CM Hospitalar S/A (BVMF:VVEO3)
Brazil · Delayed Price · Currency is BRL | Market Cap | 423.18M +8.1% |
| Revenue (ttm) | 11.57B -0.1% |
| Net Income | 18.24M |
| EPS | 0.06 |
| Shares Out | 315.81M |
| PE Ratio | 23.20 |
| Forward PE | 5.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 263,200 |
| Average Volume | 1,670,610 |
| Open | 1.360 |
| Previous Close | 1.340 |
| Day's Range | 1.280 - 1.360 |
| 52-Week Range | 0.830 - 1.860 |
| Beta | 0.62 |
| RSI | 43.40 |
| Earnings Date | May 14, 2026 |
About CM Hospitalar S/A
CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, anesthetics, anti-allergy, antibiotics, antiemetics, antifungals, anti-inflammatory, special control, several, and oncology. It also provides materials for respiratory assistance, therapy, anti-inflamma... [Read more]
Financial Performance
Financial StatementsNews
CM Hospitalar S/A Earnings Call Transcript: Q4 2025
Operational discipline and selective contract strategy led to resumed growth and margin expansion in Q4 2025. Record cash generation and improved leverage position the company for continued efficiency and profitability focus in 2026.
CM Hospitalar S/A Earnings Call Transcript: Q3 2025
Gross margin and EBITDA margin improved year-over-year, with strong cash generation and reduced net debt. Operational focus remains on efficiency, working capital, and disciplined growth, especially in hospitals and clinics, with further margin gains expected.
CM Hospitalar S/A Earnings Call Transcript: Q2 2025
Q2 2025 saw 2.5% revenue growth and 6.8% gross profit increase, with margin expansion driven by contract renegotiations and strong retail and vaccine performance. Leverage improved to 4.33x, and cash generation remains a key focus for H2.
CM Hospitalar S/A Earnings Call Transcript: Q1 2025
Gross margin reached a five-quarter high at 13.8% and expenses fell nearly 6% year-over-year, with stable adjusted EBITDA despite lower revenues. Contract renegotiations and plant consolidation are expected to drive further improvements, while all business segments are projected to grow in 2025.
CM Hospitalar S/A Earnings Call Transcript: Q4 2024
Operational integration and efficiency took priority in 2024, with a shift from rapid growth to margin and cash flow recovery. Non-recurring write-downs impacted results, but cash flow turned positive and margin recovery is expected in 2025.
CM Hospitalar S/A Earnings Call Transcript: Q3 2024
Q3 2024 saw operational stabilization, strong cash generation, and improved working capital, despite lower year-over-year margins due to mix effects and one-off provisions. Integration and cost initiatives are expected to drive further margin recovery and efficiency gains in 2025.
CM Hospitalar S/A Earnings Call Transcript: Q2 2024
Operational improvements and cost reductions drove strong cash generation and lower leverage, despite a small adjusted net loss in Q2. Inventory and working capital optimization remain priorities, with further margin and profitability gains expected from Q4 2024 onward.